Skip to content

A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation

A clinical observation of dapoxetine combined with tamsulosin in treatment of type III prostatitis with premature ejaculation

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019441
Enrollment
Unknown
Registered
2018-11-11
Start date
2017-11-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatitis complicated with premature ejaculation

Interventions

Group 1:dapoxetine combined with tamsulosin
Group 2:tamsulosin only

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
21 Years to 58 Years

Inclusion criteria

Inclusion criteria: (1) The patients had type IIIB prostatitis (according to the 2014 CUA guidelines, with pain in pelvic region and abnormal urination but urinary tract infections excluded) with PE (according to the ISSM2010 APE standard: The patient had normal sex life before but at the enrolling time the ejaculation latency was significantly shortened. More than 75% of the sex life exhibited an intravaginal ejaculation latency (IEL) < 3 min. Besides, the patient lost the ejaculation control, accompanied by pain, depression or intimacy escape, etc.); (2) Aged from 18-45 years; (3) Each of them had a regular sexual partner and a regular sex life for at least half a year (and 6 or more times of sex life in the past month); (4) They ensured 1-2 times of sex life per week during the follow-up process.

Exclusion criteria

Exclusion criteria: (1) Comorbid mental disorders, cardio-cerebrovascular diseases, liver and kidney insufficiency, alcohol dependence, hepatitis B/HCV/HIV infection, etc.; (2) Those patients with erectile dysfunction (ED, IIEF-5 score less than 21); (3) Those received serotoninergic drugs (ketamine, e.g.), SSRIs, TCAs in the last four weeks; (4) Intolerance to Priligy or tamsulosin.

Design outcomes

Primary

MeasureTime frame
NIH-CPSI;IELT;

Countries

China

Contacts

Public ContactXia shujie

Shanghai General Hospital

firsturo@163.com+86 021-63240090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026